Table 1.
Demographics and Baseline Characteristics (Safety Population)
| Characteristics | All participants (n = 45) |
|---|---|
| Age, years | 43.1 ± 13.6 |
| <65, n (%) | 41 (91.1) |
| ≥65, n (%) | 4 (8.9) |
| Female, n (%) | 28 (62.2) |
| Race, n (%) | |
| White | 41 (91.1) |
| Black or African American | 2 (4.4) |
| Native Hawaiian or other Pacific Islander | 1 (2.2) |
| Multiple | 1 (2.2) |
| Body weight, kg | 88.7 ± 19.8 |
| BMI, kg/m2 | 30.5 ± 6.4 |
| <25, n (%) | 9 (20.0) |
| ≥25 to <30, n (%) | 13 (28.9) |
| ≥30, n (%) | 23 (51.1) |
| Duration of T1D, years | 22.7 (3–50) |
| <10, n (%) | 10 (22.2) |
| ≥10, n (%) | 35 (77.8) |
| Age at onset of T1D, years | 18.0 (3–60) |
| Duration of CSII treatment, years | 8.2 (1–28) |
| Type of external pump, n (%) | |
| Animas | 4 (8.9) |
| Medtronic | 41 (91.1) |
| Screening HbA1c | |
| <8.0%, n (%) | 44 (97.8) |
| ≥8.0%, n (%) | 1 (2.2) |
| Duration of treatment with current pump, years | 2.1 (0–12) |
All data are mean ± SD or median (range) unless stated otherwise.
BMI, body mass index; CSII, continuous subcutaneous insulin infusion; HbA1c, glycated hemoglobin A1c; SD, standard deviation; T1D, type 1 diabetes.